Intra-Cellular Therapies Inc reports results for the quarter ended in December - Earnings Summary

Intra-Cellular Therapies

01/03/2023 14:33

* Intra-Cellular Therapies Inc  ITCI.OQ  reported a
quarterly
adjusted loss of 45 cents​​ per share for the quarter ended in
December. The mean expectation of thirteen analysts for the
quarter was for a loss of 59 cents per share.
    * Revenue rose 242.3% to $87.87 million from a year ago;
analysts
expected $86.97 million. 
    * Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 45 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.3%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Intra-Cellular Therapies Inc shares had fallen by 7.4%
this
quarter.
    * The company reported a quarterly loss of $44.03 million.
    * Wall Street's median 12-month price target for
Intra-Cellular
Therapies Inc is $70.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 1
at 02:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.59          -0.45          Beat
 Sep. 30 2022      -0.81          -0.57          Beat
 Jun. 30 2022      -0.76          -0.92          Missed
 Mar. 31 2022      -0.92          -0.78          Beat